| Psoriasis vulgaris

Remicade vs Lexette

Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.

Deep comparison between: Remicade vs Lexette with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsLexette has a higher rate of injection site reactions vs Remicade based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Lexette but not Remicade, including UnitedHealthcare

Category

Remicade

Lexette

At A Glance

RouteIV infusion

FrequencyEvery 8 weeks

ClassTNF-alpha inhibitor

RouteTopical

FrequencyTwice daily

ClassCorticosteroid

Indications

Crohn Disease
Ulcerative Colitis
Rheumatoid Arthritis
Arthritis, Psoriatic
Psoriasis vulgaris

Psoriasis vulgaris

Dosing

Crohn Disease, Ulcerative Colitis 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 8 weeks (adults and pediatric patients >= 6 years).

Rheumatoid Arthritis 3 mg/kg IV induction at 0, 2, and 6 weeks, then 3 mg/kg every 8 weeks in combination with methotrexate; dose may be increased up to 10 mg/kg every 8 weeks or every 4 weeks for incomplete responders.

Arthritis, Psoriatic, Psoriasis vulgaris 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 8 weeks.

Psoriasis vulgaris Apply a thin uniform film to affected skin twice daily for up to 2 weeks; shake can and invert before use; do not exceed 50 g per week; avoid face, groin, and axillae; not for use with occlusive dressings unless directed by physician.

Contraindications

Doses >5 mg/kg in patients with moderate or severe heart failure
Previous severe hypersensitivity reaction to infliximab, any inactive ingredient of REMICADE, or any murine proteins (including anaphylaxis, hypotension, and serum sickness)

—

Drug Interactions

1225View drug interactions

73View drug interactions

Adverse Reactions

Most common (>10%) Infections (upper respiratory tract infection, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain.

Serious Pneumonia, cellulitis, abscess, sepsis, bacterial infection, hepatotoxicity, acute liver failure, malignancies (including lymphoma), pancytopenia, thrombocytopenia, leukopenia.

Postmarketing Neutropenia, agranulocytosis, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, peripheral demyelinating disorders, anaphylactic shock, cerebrovascular accidents, myocardial ischemia/infarction.

Most common (>=1%) Application site burning/stinging, application site pain, headache

Postmarketing Folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, irritation, striae, miliaria

Pharmacology

TNF-alpha antagonist; infliximab is a chimeric IgG1 monoclonal antibody that neutralizes the biological activity of TNF-alpha by binding with high affinity to both soluble and transmembrane forms of TNF-alpha and inhibiting its binding to receptors, thereby reducing inflammation in RA, CD, UC, AS, PsA, and Ps.

Topical super-high potency corticosteroid; halobetasol propionate plays a role in cellular signaling, immune function, inflammation, and protein regulation, though its precise mechanism of action in plaque psoriasis is unknown.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Remicade